AGENCJA BADAŃ MEDYCZNYCH

Polfa Warszawa S.A.

Warsaw, 22 September 2023
place and date

PRICE INQUIRY No. SEMA/19/2023/API
conducted under the principles of market research

In relation to execution of the project entitled "Design and development of an innovative solution – a generic drug of the GLP-1 receptor agonist class for the treatment of type 2 diabetes", co-financed from the state budget funds in the framework of competitions conducted by the Medical Research Agency, Warszawskie Zakłady Farmaceutyczne Polfa S.A. is asking for the submission of price bids for **the purchase and supply of the active pharmaceutical ingredient Semaglutide ($C_{187}H_{291}N_{45}O_{59}$, CAS 910463-68-2), described in detail in section III**.

I. NAME AND ADDRESS OF THE CUSTOMER

Warszawskie Zakłady Farmaceutyczne Polfa S.A.
ul. Karolkowa 22/24
01-207 Warszawa

II. CONTRACT AWARD PROCEDURE

1. This contract is not subject to the provisions of the Public Procurement Law of 11 September 2019 (consolidated text: Journal of Laws of 2019, item 2019).
2. The procedure is carried out as an intended and cost-effective market inquiry, subject to the following principles:
   a) achieving the best possible results using the available resources;
   b) selecting the best possible means and methods to achieve the predefined objectives;
   c) ensuring transparency, fair competition and equal treatment of contractors.

III. DESCRIPTION OF THE SUBJECT OF THE PRICE INQUIRY

III.1. The subject of this Price Inquiry is the purchase and supply of the active pharmaceutical ingredient Semaglutide ($C_{187}H_{291}N_{45}O_{59}$, CAS 910463-68-2) obtained by **DNA recombination and chemical synthesis**, together with the related API reference standards and reference standards of impurities specific to the API.

III.2. The subject matter of the contract will be purchased from two different suppliers who will receive the highest score.

III.3. CPV CODE: 24950000-8 Specialised chemical product.

III.4. Scope of the Price Inquiry:

III.4.1. delivery of 4 grams of Semaglutide calculated with reference to the water- and sodium-free substance, together with the certificate of analysis

III.4.2. delivery of a certified API reference standard,

III.4.3. delivery of certified reference standards of API impurities contained in the specified material,

III.4.4. the proposed price should include all costs related to the delivery of the subject matter of the contract, including transport, insurance, etc.,

III.4.5. The Customer reserves the right to change the quantity of the ordered material, the active pharmaceutical ingredient semaglutide, by ±1g.

III.4.6. The remaining shelf life of the subject matter of the contract at the time of its delivery cannot be shorter than 18 months to the declared expiry date.

III.5. Partial proposals or several variants of the proposal will not be accepted.

IV. TIME AND PLACE OF DELIVERY

IV.1. Time of delivery of the subject matter of the contract:

IV.1.1. The subject matter of the contract will be delivered within 2 months of order placement.
The order will is planned to be placed with the supplier within 4 weeks of completion of the procedure.

IV.2. Place of delivery: CIP Warsaw.

V. REQUIREMENTS FOR THE CONTRACTOR

V.1. The procedure is open to any Contractor meeting all of the following requirements:

V.1.1. Having knowledge and at least 3 years of experience in the manufacture of active pharmaceutical ingredients of the therapeutic class of peptides produced by recombinant DNA technology, within the GMP quality system,

V.1.2. Having experience in preparation of the marketing authorisation dossier for active pharmaceutical ingredients of the therapeutic peptide class, confirmed by the number of submitted marketing authorisation applications,

V.1.3. Confirmation of availability and pricing of the certified API reference standard and the related declaration of recertification of the reference standard in the event of a shelf life of less than 1 year from the date of delivery

V.1.4. Confirmation of availability and pricing of certified reference standards of the specified API impurities included in the material specification, in a quantity not less than sufficient for analytical tests to be performed by the method described by the Supplier, and the associated declaration of recertification of the reference standard in the event of a shelf life of less than 6 months from the date of delivery. The final quantity will be confirmed at the order placement stage and will be estimated on the basis of the price bid presented for the package sizes that are available from the API supplier. The Customer reserves the right to change the range of the reference standards ordered, particularly in the event of overlapping impurity standards from different suppliers. In the event of overlapping impurity standards from the winning suppliers, the reference standard from the supplier proposing a lower price will be selected. The price of the reference standards declared by the manufacturer is provided in Appendix 2 hereto.

V.1.5. **declaration** of availability of the full dossier (Appendix 3),

V.1.6. **declaration** of delivery of the Applicant's Part of the ASMF/DMF after sample purchase (Appendix 3),

V.1.7. **declaration** of compliance of the active pharmaceutical ingredient with the quality requirements, including but not limited to those specified in ICH Q6A, ICH Q11, monograph EP 2034 *Substances for pharmaceutical use*, monograph USP1503 *Quality attributes of synthetic peptide drug substances*.

V.1.8. **declaration** confirming the completed evaluation of sameness of the offered substance to the active pharmaceutical ingredient of the reference product in accordance with the current FDA recommendation *ANDAs for Certain Highly Purified Synthetic Peptides Drug Products That Refer to Listed Drugs of rDNA Origin.* (Appendix 3, section 7),

V.1.9. 4 grams of Semaglutide should be derived from one certified lot which fully represents the material meeting the requirements of the final process, but the material can be manufactured under non-GMP conditions. The certificate together with the declaration that the material originates from the final manufacturing process should be attached to the bid.

Evaluation procedure:
The Customer will consider that the Contractor as fulfils the condition if the Contractor submits a declaration of compliance with the conditions for participation in the procedure (Appendix 3 to the Price Inquiry).

The Customer reserves the right to verify the fulfilment of the conditions at the Contractor's site or to request the submission of the relevant documentation.

V.2. The bids submitted by the Contractors who will demonstrate that they meet the specified requirements will pass to the stage of bid review and evaluation. Compliance with the above requirements will be evaluated using the "meets/does not meet" criterion. The bids submitted by the Contractors not meeting any one of the above requirements will be rejected.

V.3. Entities to whom the following circumstances apply are excluded from the price inquiry procedure:

a) as described in Article 7(1) of the Act of 13 April 2022 on Special Measures to Counteract Support for the Aggression against Ukraine and to Protect National Security,

b) as described in Article 5k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

Method of verification of grounds/lack of grounds for exclusion:
The verification will be carried out on the basis of the Contractor's declaration.

VI. PLACE AND DEADLINE FOR SUBMITTING BIDS:

VI.1. The deadline for submitting the price bids is 04/10/2023.
– Bids can be submitted in electronic format (a photocopy of a signed document) at barbara.wendolowska@polpharma.com

VI.2. The bid will be deemed duly submitted if the complete bid is delivered to the above e-mail address by the deadline specified in this section.

VI.3. No bids submitted past the submission deadline will be considered.

VII. EVALUATION CRITERIA

VII.1 The Customer will apply the following evaluation criteria to the received bids:

a) total net price per gram of the API Semaglutide in the form of water- and sodium-free substance – up to 25 points,

b) number of analytical techniques used to confirm the sameness of the active pharmaceutical ingredient to the reference product; the range of techniques should cover the range recommended by the FDA guidance (Appendix 3, sections 7 a-d) – up to 40 points,

c) number of batches of the reference product used in the assessment of the sameness of the API to the reference product – up to 15 points,

d) possession of the dossier compliant with the EU requirements (ASMF) and US requirements (DMF) – up to 20 points.

VII.2 The bids will be scored according to the following formula:

$$\boldsymbol{O_P = P_C + P_M + P_D + P_F}$$

where:

O_P – final score

P_C - score for the criterion: "total net price per gram of the API Semaglutide in the form of water- and sodium-free substance"

P_M - score for the criterion "number of analytical techniques used to confirm the sameness of the active pharmaceutical ingredient to the reference product, with regard to the techniques recommended by the FDA guidance"

P_D - score for the criterion "number of batches of the reference product used in the assessment of the sameness of the API to the reference product"

P_K - score for the criterion "possession of the dossier compliant with the EU requirements (ASMF) and/or US requirements (DMF)"

VII.3 Score (P_C) for the criterion "total net price per gram of the API Semaglutide in the form of water- and sodium-free substance" will be calculated according to the following formula:

$$P_C = \left[1 - \frac{(C_x - C_{min})}{(C_{max} - C_{min})}\right] * 25\ points$$

where:

P_C - score for the criterion: "total net price per gram of the API Semaglutide in the form of water- and sodium-free substance"

C_{min} - lowest total net price among the non-rejected bids

C_x - total net price in the bid under review

C_{max} - highest total net price among the non-rejected bids

The bids with the price stated in a currency other than PLN will be converted to PLN at the average exchange rate of the National Bank of Poland as at the date of the final bid submission deadline.

VII.4 The score (P_M) for the criterion "number of analytical techniques used to confirm the sameness of the active pharmaceutical ingredient to the reference product, covered by the range recommended by the FDA guidance" (Appendix 3, sections 7 a-e)" will be calculated as follows:

$$P_M = \frac{(M_x - M_{\min.})}{(M_{max} - M_{min})} * 40\ points$$

where:

- P_M - - score for the criterion "number of analytical techniques used to confirm the sameness of the API to the reference product, with regard to the techniques recommended by the FDA guidance"
- M_{min} - lowest total number of techniques used among the non-rejected bids
- M_x - total number of techniques used for the bid under review
- M_{max} - highest total number of techniques used among the non-rejected bids

VII.5 The score (P_D) for the criterion "number of batches of the reference product used in the assessment of the sameness of the API to the reference product will be calculated as follows:

$$P_D = \frac{(P_x - P_{min})}{(P_{max} - P_{min})} * 15\ points$$

where:

- P_D - score for the criterion "number of batches of the reference product used in the assessment of the sameness of the API to the reference product"
- P_{min} - lowest total number of reference product batches among the non-rejected bids
- P_x - total number of reference product batches in the bid under review
- P_{max} - highest total number of reference product batches among the non-rejected bids

VII.6 Score (P_T) for the criterion: "quality dossier compliant with the UE requirements (ASMF) and US requirements (DMF)" will be calculated as follows:

- score for the declaration of availability of the dossier compliant with the EU requirements (ASMF) – 10 points,
- score for the declaration of availability of the dossier compliant with the US requirements (DMF) – 10 points,

VII.10 The maximum score that can be awarded to the Contractor is 100. Calculations will be made to the nearest two decimal places.

VII.10.1 The subject matter of the contract will be purchased from 2 suppliers who will be awarded the highest score according to the above criteria.

VII.10.2 The reference standards of impurities will be purchased from both suppliers selected in the tender procedure. In the event of overlapping impurity standards, the reference standard from the supplier proposing a lower price will be selected.

VIII. PREPARATION OF THE BID

VIII.1. The Contractor should prepare and submit Appendix 1 and Appendix 3 at the bid submission stage, and Appendix 2 within 2 weeks after the end of the price inquiry procedure.
VIII.2. The bids may be modified or withdrawn prior to the end of their submission deadline.
VIII.3. The Contractors are required to carefully read the information contained in the Price Inquiry.
VIII.4. With any matters related to this Price Inquiry, please contact the Customer by e-mail at barbara.wendolowska@polpharma.com

IX. ADDITIONAL INFORMATION

IX.1. Any costs and expenses incurred in connection with the preparation and submission of price bids are to be borne by the respective Contractors.
IX.2. Until the deadline for price bid submission, the Customer reserves the right to change or supplement the text of this Price Inquiry.

X. LIST OF APPENDICES

The following documents are appended to this Price Inquiry:

Appendix number	Appendix title
Appendix 1	Bid form for the API
Appendix 2	Information on the bid form for the reference standards
Appendix 3	Model statement on fulfilment of the conditions defined in the Price Inquiry

Appendix 1 to the Price Inquiry No. SEMA/19/2023/API

BID FORM FOR THE API

Contractor:

Business name	
Address of the principal place of business	
E-mail address for the Customer to send correspondence related to the Price Inquiry	
NIP (Taxpayer Identification Number)	
REGON (statistical identification number)	
Phone number	
Contact person for the Customer	

Net value: …… per gram of the active pharmaceutical ingredient, calculated with reference to the water- and sodium ion-free substance, in €, $, PLN (underline as appropriate, only one currency)

for PL suppliers only: VAT rate: ……%, VAT value: …… **in €, $, PLN (underline as appropriate)**, gross value: …… **in €, $, PLN (underline as appropriate, only one currency)**

Delivery time: …….. months from the date of order placement.

We also declare as follows:

a. We have read the Price Inquiry and its appendices, and we raise no objections. We have obtained all information necessary to prepare our bid.

b. The price in our bid includes a flat-rate remuneration which covers all obligations of the future Contractor related to the performance of this contract.

c. By submitting this bid we represent that we meet the conditions for participation set out in section V of the Price Inquiry.

d. The present bid will remain valid and binding for us for 60 calendar days from the bid submission deadline.

e. By submitting this bid, we declare that none the following circumstances apply to us:

- as described in Article 7(1) of the Act of 13 April 2022 on Special Measures to Counteract Support for the Aggression against Ukraine and to Protect National Security;

- as described in Article 5k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

…… ……

(place and date) (signature)

Appendix 2 to the Price Inquiry No. SEMA/19/2023/API

BID FORM FOR THE REFERENCE STANDARDS

Bidder:

Business name	
Address of the principal place of business	
E-mail address for the Customer to send correspondence related to the Price Inquiry	
NIP (Taxpayer Identification Number)	
REGON (statistical identification number)	
Phone number	
Contact person for the Customer	

We offer the delivery of the active pharmaceutical ingredient reference standard and reference standards for the specified impurities of the active pharmaceutical ingredient at a price consistent with the price information presented in the table below (price specified for the different available weights for the order):

API reference standard

	API reference standard
Required quantity for a single analysis (g)	…… **(g)**
Minimum pack size of the reference standard (g)	…… **(g)**
Price for the smallest pack size in **€, $, PLN** (mark as appropriate)	……. ……. **net,** …….. …… **gross**
If the Contractor has different pack volumes, please specify **Pack sizes, net prices, gross prices in** **€, $, PLN** (mark as appropriate)	……. **(g),**…..… **net,** ……... **gross** ……. **(g),**…..… **net,** ……... **gross** ……. **(g),**…..… **net,** ……... **gross**

Impurity standard No. …..*

Impurity reference standard		
Name used by the Supplier		
Chemical name		
Chemical formula		
Quantity required for a single analysis (g)		**……. (g)**
Minimum pack size (g)		**…….. (g)**
Price for the smallest pack **€, $, PLN** (underline as appropriate)		**…… net, …….. gross**
If the Contractor has different pack volumes, please specify Pack sizes, net prices, gross prices in **€, $, PLN** (mark as appropriate)		**……. (g),……. net, ……..... gross** **……. (g),……. net, ……..... gross** **……. (g),……. net, ……..... gross**

***If more impurities are present, please copy the table of standards for impurities, assigning subsequent numbers.**

…… ……

(place and date) (signature)

Appendix 3 to the Price Inquiry No. SEMA/19/2023/API

STATEMENT ON FULFILMENT OF THE CONDITIONS DEFINED IN THE PRICE INQUIRY

… … … … ….. (business/Contractor) declares that it meets the conditions specified in the Price Inquiry, in accordance with the table below:

No.	Criteria	Yes/No	Value
1	having knowledge and experience in the manufacture of active pharmaceutical ingredients of the therapeutic class of peptides in compliance with the GMP quality system,		Number of years ……..
2	having experience in preparation of the marketing authorisation dossier for active pharmaceutical ingredients of the therapeutic peptide class		Number of submitted marketing authorisation applications……..
3	availability of the certified semaglutide reference standard and reference standards for the specified impurities of the active pharmaceutical ingredient included in the specification of the material in accordance with section V.I.3. and submission of Appendix 2 for the standard material within 2 weeks of the end of the price inquiry procedure		
4	after the purchase, submission of a sample of the Applicant's Part of the ASMF/DMF or related documents, such as the specification of the material, description of the substance control methods used, detailed description of impurities, source of impurities, stress tests, minimum stability period of 6 months under accelerated conditions (minimum 2 batches) and evidence of sameness of the substance		
5a	Availability of the full dossier: DMF		availability date……..
5b	Availability of the full dossier: ASMF		availability date ……..
6	The active pharmaceutical ingredient meets the respective quality requirements, including but not limited to those specified in ICH Q6A, ICH Q11, monograph EP 2034 Substances for pharmaceutical use, monograph		

	USP1503 Quality attributes of synthetic peptide drug substances.		
7	Presentation of the declaration confirming the sameness of the offered substance to the active pharmaceutical ingredient of the reference product in accordance with the current FDA recommendation ANDAs for Certain Highly Purified Synthetic Peptides Drug Products That Refer to Listed Drugs of rDNA Origin, and presentation of results of tests of the active pharmaceutical ingredient within 2 weeks of purchase, including		
7a	Comparison of the primary structure and sequence of the peptide,		number of methods used …….. number of batches: API …… number of batches: RLD ……..
7b	Comparison of the secondary structure,		number of methods used …….. number of batches: API …… number of batches: RLD ……..
7c	Comparison of the higher order structures/aggregates		number of methods used …….. number of batches: API …… number of batches: RLD ……..
7d	Demonstration of equivalent biological activity, preferably using an in vitro test method		number of methods used …….. number of batches: API …… number of batches: RLD ……..
7e	Confirmation of a similar profile and level of impurities (impurities not higher than in the reference drug),		
7f	Other tests confirming the sameness of the active pharmaceutical ingredient to the reference product		number of methods used …….. number of batches: API …… number of batches: RLD ……..
8	Semaglutide samples are derived from one certified lot which fully represents the material originating from the final process, but the lot can be manufactured under non-GMP conditions. The certificate should be appended to the bid together with the declaration that the material originates from the final manufacturing process.		

…… ……

(place and date) (signature)